earnings
confidence high
sentiment negative
materiality 0.70
Amphastar Q2 2025 revenue $174.4M, GAAP EPS $0.64; BAQSIMI sales up 21%
Amphastar Pharmaceuticals, Inc.
2025-Q2 EPS reported
$1.15
revenue$344,942,000
- Net revenues $174.4M vs $182.4M YoY; GAAP net income $31.0M ($0.64 diluted EPS).
- Adjusted non-GAAP net income $40.9M ($0.85 diluted EPS) vs $48.7M ($0.94) YoY.
- BAQSIMI sales increased 21% YoY, cited as key revenue driver.
- Announced multi-year plan to quadruple manufacturing capacity at Rancho Cucamonga HQ.